# A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

> **NCT06383767** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 378 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** ESG401
- **DRUG:** Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)

## Key facts

- **NCT ID:** NCT06383767
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-07-31
- **Target enrollment:** 378 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06383767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06383767, "A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06383767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*